Biosimilars Council Applauds FDA’s Efforts To Hear From Industry About Biosimilar Development
Comments On Biosimilar Development Are Welcomed Until 23 October
The US FDA is all ears. Stakeholders in the biosimilar industry have a chance to give their two cents about what would work best for development guidance.
